Advancing Treatment for EGFR-Mutant Advanced NSCLC: Lessons from FLAURA2

Author(s):

Helena A. Yu, MD, discusses her treatment strategy for patients with EGFR-mutant non-small cell lung cancer (NSCLC), emphasizing current guidelines and standard of care, while Zosia Piotrowska, MD, MHS, examines the key efficacy and safety findings from the FLAURA2 study, which evaluated first-line osimertinib combined with chemotherapy in patients with advanced EGFR-mutant NSCLC.

EP: 1.Treatment Strategies for NSCLC with Non-Actionable Mutations

EP: 2.Role of Antibody-Drug Conjugates in NSCLC Treatment: Insights from EVOKE-02

EP: 3.Exploring the TROPION-Lung04 Study

EP: 4.Exploring Dato-DXd Combinations as First-Line Therapy for Advanced NSCLC

EP: 5.Navigating Between ADCs in NSCLC

Now Viewing

EP: 6.Advancing Treatment for EGFR-Mutant Advanced NSCLC: Lessons from FLAURA2

EP: 7.Osimertinib Monotherapy vs. Combination Therapy: Patient Selection in EGFR-Mutant Advanced NSCLC

EP: 8.MARIPOSA Study Insights

EP: 9.Optimizing Therapy Selection in EGFR Mutant NSCLC

EP: 10.ASCO 2024 Updates: Novel Approaches in NSCLC Therapy

EP: 11.Overview of TROP2 & Potential Role of TROP2-Directed ADCs in NSCLC

EP: 12.Key Takeaways from TROPION Trials: Implications for NSCLC Treatment Landscape

EP: 13.Targeting of HER3: Insights from HERTHENA-Lung01

EP: 14.Challenges and Learnings from EVOKE-01

EP: 15.Key ADC Studies at ASCO 2024

EP: 16.Mitigating Toxicities of Dato-DXd, Sacituzumab Govitecan, and HER3-DXd

EP: 17.Patient Selection and Sequencing of NSCLC ADCs

Briefly discuss your general treatment approach in patients with EGFR-mutant NSCLC.
- What treatment options are available? What is the standard of care in this setting?
- What factors do you consider in guiding treatment selection?
Please review key efficacy and safety data from FLAURA2 evaluating 1L osimertinib with chemotherapy in patients with EGFR-mutant advanced NSCLC.(Janne, et al. WCLC 2023. Abstract PL03.13; Planchard, et al. ESMO 2023. Abstract LBA68)
- What implications may these findings have on clinical practice?